Globalagliatin Hydrochloride vs HMS1005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Globalagliatin Hydrochloride
Developed by Eli Lilly and partners
NCT03414892 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
the mean change in glucose area under curve (AUC) from baseline. (28 days): Phase Ib, 28-day multiple ascending dose study of globalagliatin (glucokinase activator) in 24 Chinese T2DM patients (3:1 randomization, NCT03414892): high-dose globalagliatin significantly reduced FPG by LS mean -4.08 mmol/L (95% CI -5.05 to -3.12, P<0.01) vs placebo, plus significant reductions in 24-h glucose AUC and glycated albumin; mildly elevated incidences of hypoglycemia and hypertriglyceridemia; well tolerated with favorable PK. (met)
Result source: NCT03414892
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
Reported efficacy
Incidence of adverse events (11 Days); Area under the plasma concentration versus time curve (AUC) (72 hour); maximum observed concentration (Cmax) (72 hours); time of the maximum observed concentration (Tmax) (72 hours); apparent terminal elimination half life (t1/2) (72 hours): US Phase Ia single ascending dose study, 40 T2D subjects: HM-002-1005 near-completely converts to HMS5552 (dorzagliatin) in vivo; prolonged half-life vs dorzagliatin; Cmax at 184.5mg single dose comparable to 75mg single dose of dorzagliatin
Result source: NCT06498284
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Globalagliatin Hydrochloride | HMS1005 |
|---|---|---|
| HbA1c, change | —Not reported | —Not reported |
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Globalagliatin Hydrochloride
- —Not reported
- HMS1005
- —Not reported
Body weight, change (kg)
- Globalagliatin Hydrochloride
- —Not reported
- HMS1005
- —Not reported
HbA1c below 7%
- Globalagliatin Hydrochloride
- —Not reported
- HMS1005
- —Not reported
Fasting plasma glucose, change
- Globalagliatin Hydrochloride
- —Not reported
- HMS1005
- —Not reported
3-point MACE (% with event)
- Globalagliatin Hydrochloride
- —Not reported
- HMS1005
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HMS1005: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Globalagliatin Hydrochloride's landscape · HMS1005's landscape